CSIMarket
 
Krystal Biotech Inc   (KRYS)
Other Ticker:  
 
 
Price: $168.5300 $-4.45 -2.573%
Day's High: $172.32 Week Perf: -5.82 %
Day's Low: $ 165.56 30 Day Perf: 48.64 %
Volume (M): 387 52 Wk High: $ 189.97
Volume (M$): $ 65,289 52 Wk Avg: $115.03
Open: $171.61 52 Wk Low: $72.18



 Market Capitalization (Millions $) 4,724
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) 51
 Net Income (TTM) (Millions $) 11
 Cash Flow (TTM) (Millions $) 196
 Capital Exp. (TTM) (Millions $) 12

Krystal Biotech Inc
Krystal Biotech Inc is a biotechnology company that specializes in developing gene therapy treatments for various skin disorders. The company focuses on leveraging its proprietary skin-targeted gene therapy platform to create highly effective and minimally invasive treatments for diseases such as epidermolysis bullosa and other genetic skin conditions. Krystal Biotech aims to improve the lives of patients through innovative gene therapy solutions and is dedicated to advancing the field of gene therapy for dermatological diseases.


   Company Address: 2100 Wharton Street Pittsburgh 15203 PA
   Company Phone Number: 586-5830   Stock Exchange / Ticker: NASDAQ KRYS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Krystal Biotech Inc

Krystal Biotech Inc's Fourth Quarter Results: Revenue Reaches $42.143 Million 2.

The recent financial results of Krystal Biotech Inc, a biotechnology and pharmaceutical company, have showcased significant improvements and positive trends. In the fourth quarter of 2023, the company achieved revenue of $42.143 million, indicating promising growth in its operations.
One of the most notable achievements is the company's bottom-line improvement. In the fourth quarter of 2023, Krystal Biotech Inc reported a net profit of $8.692 million, contrasting with a net deficit of $-32.052 million in the same reporting period the previous year. This indicates a substantial turnaround and highlights the company's ability to manage its finances and improve profitability.

Clinical Study

Krystal Biotech's B-VEC Demonstrates Remarkable Efficacy in Treating Ocular Complications in Dystrophic Epidermolysis Bullosa Patients, Published in the New England Journal of Medicine

Published Thu, Feb 8 2024 12:00 PM UTC

Krystal Biotech's Groundbreaking B-VEC Treatment: A Promising Breakthrough for Ocular Complications in Dystrophic Epidermolysis Bullosa PatientsKrystal Biotech has recently published a groundbreaking study in the prestigious New England Journal of Medicine, shedding light on the remarkable potential of their B-VEC treatment in managing ocular complications in patients with D...

Product Service News

Krystal Biotech's Breakthrough Treatment Granted Orphan Drug Designation in Japan, Opening New Avenues for Rare Disease Patients

Published Tue, Dec 19 2023 12:00 PM UTC


PITTSBURGH, Dec. 19, 2023 - Krystal Biotech Inc, a leading biotechnology company specializing in the development of genetic medicines for diseases with high unmet medical needs, has announced that it has been granted Orphan Drug Designation (ODD) by the Japan Ministry of Health, Labour and Welfare (MHLW). This designation is for their innovative treatment, beremagene ge...

Product Service News

Krystal Biotech's Revolutionary Genetic Medicine, VYJUVEK, Poised to Transform Dystrophic Epidermolysis Bullosa Treatment Landscape

Published Mon, Nov 27 2023 12:00 PM UTC



PITTSBURGH, Nov. 27, 2023 ? Krystal Biotech, Inc. (NASDAQ: KRYS), a renowned biotechnology firm specializing in the discovery, development, and commercialization of genetic medicines to address diseases with significant unmet medical needs, has announced the validation of its Marketing Authorization Application (MAA) for VYJUVEK (beremagene geperpavec-svdt, also kn...

Krystal Biotech Inc

Krystal Biotech Inc Announces Impressive Q3 2023 Financial Report, Generates Revenue of $8.556 Million

Krystal Biotech Inc, a biotechnology company specializing in gene therapies, recently released their financial results for the financial period ending September 30, 2023. These results indicate positive growth and improvement for the company.
In terms of revenue, Krystal Biotech Inc disclosed $8.556 million in sales during this financial period. This indicates a consistent growth in sales compared to the previous year. Additionally, the company reported net profits of $80.747 million, a significant improvement from the net deficit of $-29.850 million in the same financial reporting period a year ago. This positive swing in profitability showcases the company's successful efforts in expanding its market presence and increasing the demand for its products.






 

Krystal Biotech Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Krystal Biotech Inc does not provide revenue guidance.

Earnings Outlook
Krystal Biotech Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com